- Home
- ICON vs VIVS Comparison
ICON vs VIVS Comparison
Compare ICON & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- VIVS
- Stock Information
- Founded
- ICON 2023
- VIVS 2007
- Country
- ICON Greece
- VIVS United States
- Employees
- ICON N/A
- VIVS N/A
- Industry
- ICON
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICON
- VIVS Health Care
- Exchange
- ICON Nasdaq
- VIVS Nasdaq
- Market Cap
- ICON 5.2M
- VIVS 5.0M
- IPO Year
- ICON 2024
- VIVS N/A
- Fundamental
- Price
- ICON $2.37
- VIVS $1.90
- Analyst Decision
- ICON Strong Buy
- VIVS
- Analyst Count
- ICON 1
- VIVS 0
- Target Price
- ICON $4.50
- VIVS N/A
- AVG Volume (30 Days)
- ICON 206.5K
- VIVS 80.7K
- Earning Date
- ICON 09-09-2025
- VIVS 08-12-2025
- Dividend Yield
- ICON 396.62%
- VIVS N/A
- EPS Growth
- ICON N/A
- VIVS N/A
- EPS
- ICON N/A
- VIVS N/A
- Revenue
- ICON $6,137,000.00
- VIVS $144,000.00
- Revenue This Year
- ICON $51.78
- VIVS $42.38
- Revenue Next Year
- ICON $51.90
- VIVS $15.42
- P/E Ratio
- ICON N/A
- VIVS N/A
- Revenue Growth
- ICON 16.93
- VIVS 32.11
- 52 Week Low
- ICON $1.60
- VIVS $1.41
- 52 Week High
- ICON $130.80
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- VIVS N/A
- Support Level
- ICON N/A
- VIVS N/A
- Resistance Level
- ICON N/A
- VIVS N/A
- Average True Range (ATR)
- ICON 0.00
- VIVS 0.00
- MACD
- ICON 0.00
- VIVS 0.00
- Stochastic Oscillator
- ICON 0.00
- VIVS 0.00
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.